The Lifesciences Magazine

  A recently conducted study may provide regulators with sufficient evidence to consider the use of MDMA, also known as Ecstasy, as a potential treatment for PTSD (post-traumatic stress disorder). The study, published on Thursday, suggests that MDMA therapy is effective in reducing symptoms of PTSD. This research represents the final trial conducted by MAPS Public Benefit Corporation, a company dedicated to developing prescription psychedelics. They intend to submit the study’s findings to the Food and Drug Administration (FDA) as part of an application seeking approval to market MDMA therapy, the psychedelic drug , as a treatment for PTSD when combined with talk therapy. First novel treatment for PTSD If approved, this would mark a significant milestone, as “MDMA therapy would be the first novel treatment for PTSD in over two decades,” stated Berra Yazar-Klosinski, the senior author of the study published in Nature Medicine and the chief scientific officer at the company. This dev...